Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Temporal predictors of SARS-CoV-2 antibodies

Researchers in a recent paper published as a preprint on the preprint medRxiv, study the clinical factors, the laboratory assays to streamline plasma donor selection, and the durability of nAb responses in adults.

11 Oct 2020

Vaccines likely to be effective against SARS-CoV-2 D614G mutation

The emergence of the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutation D614G has raised many questions, including whether it will cause the virus to become resistant to the vaccines produced against earlier versions of the virus. A new study published in the journal npj Vaccines in October 2020 shows that this may be an unfounded fear.

11 Oct 2020

Rapid and sensitive detection of SARS-CoV-2 with functionalized magnetic nanoparticles

A recent study published on the preprint server arXiv in October 2020 shows the potential for using functionalized magnetic nanoparticles to detect the presence of the virus in a sample.

11 Oct 2020

Exciting findings on CD8 T cell response in recovered COVID patients

An international team of scientists has identified novel T cell-recognized epitopes spanning different proteins of severe acute respiratory syndrome coronavirus 2 in COVID-19 recovered patients. The scientists have also revealed phenotypical characteristics of the T cell population.

11 Oct 2020

Too little sugar is the cause of perforated bones

Bone marrow cancer is currently an incurable disease that affects about 400 people in Norway every year. Professor Therese Standal at NTNU has now found an important reason for bone destruction in people with this disease.

9 Oct 2020

Antibody cocktail may offer clinical benefit in both prevention and treatment of COVID-19

In June, two studies in Science reported an antibody cocktail against SARS-CoV-2 developed from studies in humanized mice and recovering patients. The two antibody cocktail was designed to bind the virus to reduce the risk of a drug-resistant form emerging.

9 Oct 2020

Serum antibodies from SARS-CoV patients effectively neutralized SARS-CoV-2 in cultured cells

Antibodies in serum samples collected from patients infected with SARS-CoV during the 2003 outbreak effectively neutralized SARS-CoV-2 infection in cultured cells, according to a new study.

9 Oct 2020

Exuberant activation of immune cells in severe COVID-19 resembles lupus

In severe cases of COVID-19, Emory researchers have been observing an exuberant activation of immune cells, resembling acute flares of systemic lupus erythematosus (SLE), an autoimmune disease.

9 Oct 2020

Key insights into harnessing the tools of population health to combat COVID-19

Battling the COVID-19 pandemic and preparing for the inevitable next surge requires a data-driven population health approach.

9 Oct 2020

As Trump touts his ‘great’ COVID drugs, the pharma cash flows to Biden, not him

Pharmaceutical giants Regeneron and Gilead Sciences got the kind of publicity money can't buy this week after President Donald Trump took their experimental drugs for his coronavirus infection, left the hospital and pronounced himself fully recovered.

9 Oct 2020

Long-lasting antibodies detected in blood and saliva of COVID-19 patients

Two separate studies have documented the persistence of antibodies that target SARS-CoV-2 in hundreds of patients with COVID-19 at least 3 months after symptom onset.

9 Oct 2020

University of Minnesota Medical School chosen as ‘Capacity Building Center’ for national network

The University of Minnesota Medical School's Department of Laboratory Medicine and Pathology has been selected to participate in a new national network dedicated to serological, or antibody, sciences as one of four Capacity Building Centers in the country.

9 Oct 2020

Novel radioimmunotherapy proven effective in reversing resistance to lymphoma therapy

A new radioimmunotherapy has proven effective in reversing resistance to the most commonly used lymphoma drug, rituximab, according to research published in the October issue of The Journal of Nuclear Medicine.

8 Oct 2020

Mount Sinai to receive more than $7.3 million as part of NCI's new Serological Sciences Network

Researchers from the Icahn School of Medicine at Mount Sinai will receive more than $7.3 million from the National Cancer Institute as part of the NCI's new Serological Sciences Network (SeroNet), one of the largest coordinated national efforts to study immunology and SARS-CoV-2, the virus that causes COVID-19.

8 Oct 2020

NIH clinical trial to test a combination treatment regimen for COVID-19

A clinical trial to test the safety, tolerability and efficacy of a combination treatment regimen for coronavirus disease 2019 (COVID-19) consisting of the antiviral remdesivir plus a highly concentrated solution of antibodies that neutralize SARS-CoV-2, the virus that causes COVID-19, has begun.

8 Oct 2020

Neutralizing responses to infection relatively common in COVID-19

A new study has shown that severe coronavirus disease 2019 (COVID-19) is associated with unique B cell receptor (BCR) signatures and multiclonal neutralizing responses against the causative agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

8 Oct 2020

Study estimates lower herd immunity to SARS-CoV-2 in the U.S.

A new study shows that recognizing the differences in the population composition, connectedness and distribution, as well as inter-individual differences in immunity, susceptibility and infectivity, are crucial to estimating the herd immunity attained as a result of natural severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) more accurately.

8 Oct 2020

Novel feed ingredient can reduce effects of coccidiosis in broiler chickens

Broiler chicken producers the world over are all too familiar with coccidiosis, a parasite-borne intestinal disease that stalls growth and winnows flocks.

8 Oct 2020

Experimental Chinese SARS-CoV-2 vaccine appears safe in early trials

A new study published on the preprint server medRxiv in October 2020 reports the findings of a phase I trial of an inactivated SARS-CoV-2 vaccine, demonstrating that it can elicit a potent immune response without significant adverse reactions.

7 Oct 2020

Proteolytic cleavage of nucleocapsid helps SARS-CoV-2 evade host immune responses

A team of scientists of the University of Oxford reveals that the nucleocapsid protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) undergoes autoproteolysis, and that resulting products can escape the host immune responses and facilitate viral proliferation. The study is currently available on the bioRxiv preprint server.

7 Oct 2020